Sarepta Therapeutics (SRPT) Stock
Biotech developing genetic medicines for rare muscular dystrophy. Here's the price, business snapshot, and what's worth knowing about Sarepta Therapeutics in July 2026.
Sarepta Therapeutics (SRPT) is a US‑based biotechnology company focused on genetic medicines for rare neuromuscular conditions, principally Duchenne muscular dystrophy (DMD). Its portfolio includes exon‑skipping oligonucleotides with prior regulatory approvals and a developing gene‑therapy pipeline aimed at restoring dystrophin expression. The company’s clinical updates, regulatory interactions and manufacturing progress tend to drive short‑term share‑price moves. With a market capitalisation of about $2.44 billion, Sarepta is a small‑to‑mid‑cap biotech where R&D outcomes heavily influence valuation. Investors should note high development costs, potential for binary clinical outcomes and ongoing debates about clinical efficacy in some programmes. Commercial revenues exist but remain modest relative to R&D expenditure, so partnerships and successful trial readouts are key. This content is educational only and not personal financial advice; biotech stocks can be volatile and may suit only investors with a higher tolerance for risk and a longer time horizon.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Sarepta Therapeutics’ stock with a target price of $117.6, indicating potential growth.
Financial Health
Sarepta Therapeutics is performing well with strong revenue and good profit margins, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring SRPT
RNA Stocks (M&A Targets) Could See Premium Valuations
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Published: 27 October 2025
Explore BasketOrphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: 20 August 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: 30 July 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: 29 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory decisions can move the shares sharply; successful trials may materially change the outlook, though outcomes are uncertain.
Binary Outcome Risk
Many programmes face all‑or‑nothing trials and manufacturing hurdles, so single events can cause large share‑price swings and volatility.
Commercial & Partnerships
Revenue growth depends on market uptake, payer coverage and collaborations; commercial progress matters alongside science, yet sales may lag R&D spend.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
